Why Is Tiziana Life Sciences Stock Gaining Thursday?
Tiziana Life Sciences (TLSA) stock jumps 21% following an MOU to test intranasal foralumab combo therapy for MS.
Stocks · News reference
Tiziana Life Sciences shares are trading higher after the company announced quantitative PET imaging results from the third patient with Multiple System Atrophy in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tiziana Life Sciences shares are trading higher after the company announced the signing of a a Memorandum of Understanding with the King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases to collaborate on a clinical trial evaluating a combination of the proprietary intranasal foralumab and existing anti-CD20 therapy in patients with relapsing-remitting multiple sclerosis who are responding poorly to anti-CD20 therapy alone.
Tiziana Life Sciences Announces MOU With King Abdullah International Medical Research Center And Foundation For Neurologic Diseases For Trial Of Intranasal Foralumab With Anti-CD20 Therapy In Relapsing-Remitting MS
Tiziana Life Sciences shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a $7 price target.